Motixafortide + G-CSF boosts CD34+ HSPCs in MM patients for ASCT

Crees ZD, Rettig MP, Jayasinghe RG, et al. Motixafortide and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A Randomized Phase 3 Trial. Nature Medicine. 2023; (doi: 10.1038/s41591-023-02273-z).

A single injection of motixafortide + granulocyte colony-stimulating factor (G-CSF) in multiple myeloma (MM) patients undergoing autologous stem cell transplantation mobilized more CD34+ hematopoietic stem and progenitor cells (HSPCs) within two apheresis procedures compared with placebo + G-CSF, new research shows. The randomized Phase 3 GENESIS trial enrolled 122 adult MM patients in five nations in a 2:1 ratio for motixafortide + G-CSF (N=80) or placebo + G-CSF (N=42) for HSPC mobilization. With motixafortide + G-CSF, 92.5% of patients met the primary endpoint of mobilizing ≥6 x 10 6 CD34+ cells kg-1 in two apheresis procedures, compared with 26.2% in the placebo group. The secondary endpoint — achieving the same mobilization in one apheresis procedure — was achieved in 88.8% of patients in the motixafortide + G-CSF group and in 9.5% of the placebo + G-CSF group. The most common treatment-emergent adverse events associated with motixafortide + G-CSF were transient, grade 1/2 injection site reactions, including pain, erythema, and pruritis.

Read More

Tags: patient care, multiple myeloma, transplantation, Cellular therapy, hematopoietic, Research, Transplant, cell therapy, trials, MM